Max Neeman International Expands Upon Cardiology and Device Trial Experience to Meet Increased Medical Device Development in India
RESEARCH TRIANGLE PARK, N.C., Sept. 13 /PRNewswire/ -- Max Neeman International, a leading Indian CRO, announces the expansion of therapeutic focused device clinical trial services in India. Max Neeman has formed an experienced and world class team of medical device experts specializing in carrying out cardiac device trials – therapeutic, diagnostic and surgical. Coronary artherectomy, cardiac stents, aneurysm, mitral valve regurgitation and acute coronary syndrome form 90% of the total device trial experience. These are multicentric global trials with patients as high as 300. Along with prior experience of conducting device trials, the specialized Max Neeman team and services adds an enhanced level of company expertise in conducting simple to complex device studies. Max Neeman also has medical device operations and regulatory experience in various other device therapeutic areas as well including CNS and Ophthalmology.
India is emerging as a destination of choice for medical device development and conducting device trials as the market for percutaneous coronary interventions has expanded. India's device market is currently valued at US $1.7 Billion and projected to grow at the rate of 23% annually. Benefits which have accelerated outsourcing of device trials to India include: shortened product development cycle, faster time to market (by approximately 30% due to faster patient recruitment) and testing resulting in significant cost savings of about 40-50%. Max Neeman International conducts device studies for small to large device firms across the globe delivering high quality results at a lower cost resulting in high client satisfaction.
About Max Neeman International
Max Neeman International is one of the leading and largest CROs in India. Our specialty is that we offer services for the successful conduct of Phase I-IV clinical and device trials for small and mid-sized international and na